Hormone therapy is not a set-it-and-forget-it intervention. Levels drift, doses need adjustment, and the markers that were normal at baseline can change after 6 months of treatment. Tracking hormone levels over time with structured lab monitoring is what separates a protocol that works from one that slowly stops working without anyone noticing. This guide covers the lab schedule, the markers to track, and the patterns that signal a protocol needs adjustment.
- The lab schedule runs baseline → 6-8 weeks → 3 months → 6 months → every 6-12 months once stable
- Markers tracked depend on therapy: testosterone (trough testosterone, estradiol, hematocrit), estrogen (estradiol, progesterone, endometrial monitoring), thyroid (TSH, free T4)
- Symptoms are unreliable for dose adjustment — lab levels and symptoms together are the standard
- Hormone levels drift due to weight loss, aging (SHBG shifts), stress/sleep disruption, and seasonal vitamin D changes
- Keeping a personal record of lab results over time helps identify drift and supports long-term protocol management
TL;DR
Tracking hormone levels over time requires a structured lab schedule: baseline before starting therapy, follow-up at 6-8 weeks, 3 months, 6 months, then every 6-12 months once stable. The markers tracked depend on the therapy — testosterone therapy requires trough testosterone, estradiol, and hematocrit; estrogen therapy requires estradiol, progesterone, and endometrial monitoring; thyroid therapy requires TSH and free T4. Verdict: the patients whose protocols work long-term are the ones whose clinicians recheck labs on a schedule, not the ones who feel fine and skip the follow-up. Symptoms are unreliable for dose adjustment — lab levels and symptoms together are the standard.
Why This Matters
Hormone levels change for reasons unrelated to the dose: weight loss improves insulin sensitivity and can reduce the testosterone dose needed; aging shifts SHBG upward, changing free testosterone even if total stays the same; seasonal vitamin D fluctuations affect testosterone production; stress and sleep disruption raise cortisol, which suppresses reproductive hormones. A protocol that was perfect at month 2 may be under-dosed at month 8 because the patient lost 20 pounds and their insulin resistance improved — or it may be over-dosed because their SHBG dropped, increasing free testosterone beyond the target range.
Without structured lab tracking, these changes go unnoticed until symptoms appear — at which point the adjustment is reactive instead of proactive. The difference between a protocol that works for years and one that stops working at month 6 is often not the initial dose; it's whether someone was watching the labs.
The difference between a protocol that works for years and one that stops working at month 6 is often not the initial dose; it's whether someone was watching the labs.
What You'll Need
- Baseline labs before starting any hormone intervention
- A clinician who maintains a monitoring schedule and contacts you when labs are due
- A personal record of your lab results over time — not just the most recent draw
- A symptom journal tracking energy, mood, libido, sleep, and any side effects weekly
- An understanding of which markers are tracked for your specific therapy (see below)
- Access to lab draws at the intervals your clinician recommends
The Steps
1. Establish the baseline before starting therapy
Before any hormone intervention, the clinician orders the full baseline panel. For men starting testosterone therapy: total and free testosterone, SHBG, estradiol, LH, FSH, PSA (if over 40), hematocrit, lipid panel, fasting insulin, and TSH. For women starting hormone replacement: estradiol, progesterone, FSH, LH, free testosterone, DHEA-S, TSH, free T4, free T3, fasting insulin, and SHBG. For thyroid medication: TSH, free T4, free T3, and anti-TPO antibodies. These baseline values are the reference point for every future comparison. Common mistake: starting therapy without baseline labs, making it impossible to know whether the protocol actually moved the markers.
2. Schedule the first follow-up at 6-8 weeks
The 6-8 week follow-up is the most important checkpoint in hormone therapy. For testosterone: check trough testosterone (drawn immediately before the next dose), estradiol, and hematocrit. For estrogen therapy: check estradiol and progesterone. For thyroid: check TSH and free T4 (6 weeks after any dose change — this is the interval the thyroid axis needs to equilibrate). This is where the clinician confirms the dose is in the target range and catches early side effects before they become problems. Common mistake: skipping the 6-8 week follow-up because symptoms have improved — symptoms can improve before levels are stable, and the dose may still need adjustment.
Symptoms can improve before levels are stable, and the dose may still need adjustment — skipping the 6-8 week follow-up because symptoms feel fine is a common mistake.
3. Track the right markers for your therapy
Lab Markers by Therapy Type
targets as tracked in this guide
| Therapy | Markers Tracked | Target Range |
|---|---|---|
| Testosterone therapy | Trough testosterone, estradiol, hematocrit, PSA (baseline plus annual) | Trough testosterone 400-600 ng/dL; estradiol below 40 pg/mL; hematocrit below 52% |
| Estrogen therapy (women) | Estradiol, progesterone, endometrial monitoring (annual ultrasound if on continuous estrogen) | Estradiol typically 50-100 pg/mL for menopausal symptom relief; progesterone above 5 ng/mL on day 21 or on continuous therapy |
| Thyroid therapy | TSH, free T4, free T3 | TSH 0.5-2.5 mIU/L for most patients |
Track LH and FSH only if evaluating fertility preservation. Common mistake: tracking only the hormone being replaced and ignoring downstream markers — testosterone converts to estradiol, thyroid medication affects SHBG, estrogen therapy affects thyroid binding.
4. Recheck at 3 and 6 months, then every 6-12 months
At 3 months, confirm the dose is stable and symptoms have resolved. At 6 months, do a full panel recheck — not just the hormone being replaced but the full metabolic and hormonal picture, since interventions in one system can affect others. Once stable for 6 months, annual or biannual rechecks are sufficient unless symptoms change. Common mistake: assuming that because the 6-week follow-up was good, no further monitoring is needed — levels drift over months, and the 3-month and 6-month checkpoints catch drift before symptoms appear.
5. Watch for patterns that signal a needed adjustment
Symptoms return despite stable labs: Check SHBG — if it has changed, free hormone levels may have shifted even if total is stable. Also evaluate cortisol, thyroid, and insulin — a new metabolic issue may be producing symptoms that mimic hormone deficiency.
Side effects appear at 3-6 months that weren't present initially: The body's aromatase activity may have increased (more testosterone converting to estradiol), or hematocrit may have climbed gradually. Check estradiol and hematocrit.
Weight loss of 10+ pounds: Insulin sensitivity improves, SHBG may shift, and the required dose of testosterone or thyroid medication may decrease. Recheck labs and adjust.
New medication added by a specialist: Some medications interact with hormone therapy — glucocorticoids suppress testosterone, anticonvulsants accelerate hormone metabolism, SSRIs can affect libido independently. Recheck labs after any new medication is introduced.
Common mistake: attributing symptom changes to life stress or aging when the lab pattern shows a clear drift that a dose adjustment would fix.
6. Keep your own record of lab results over time
Request copies of every lab result and maintain a simple spreadsheet or document tracking the key markers, dates, and doses. This record is invaluable when switching clinicians, evaluating long-term trends, or identifying a pattern that a single draw wouldn't reveal. A clinician who has your 2-year lab history makes better decisions than one who has only the most recent draw. Common mistake: relying on the clinician's chart as the only record — if you switch practices, the history may not transfer cleanly.
Troubleshooting Common Setbacks
Labs are stable but symptoms have returned. Check for a new contributing factor — thyroid drift, sleep disruption, stress, weight change, or a new medication. The hormone protocol may be fine; the symptom driver may have changed.
Testosterone levels are in range but estradiol is climbing. Reduce the dose slightly or switch to more frequent, smaller injections. Elevated estradiol causes fatigue, water retention, and mood changes.
TSH has risen despite stable thyroid medication dose. Check for new interactions (calcium or iron supplements taken within 4 hours of thyroid medication), weight gain, or seasonal variation. Adjust the dose and recheck in 6 weeks.
Hematocrit is creeping up over successive draws. Switch to smaller, more frequent injections or reduce the dose slightly. If hematocrit exceeds 54%, therapeutic phlebotomy may be needed.
If hematocrit exceeds 54%, therapeutic phlebotomy may be needed — a pattern of creeping hematocrit over successive draws should prompt smaller, more frequent injections or a dose reduction before it reaches that threshold.
Tools and Resources
- A personal lab tracking spreadsheet: marker, value, date, dose at time of draw
- A clinician who maintains a monitoring schedule and contacts you when labs are due — a direct primary care membership is designed for this
- A hormone optimization program with structured follow-up at 6-8 weeks, 3 months, and 6 months
- A symptom journal tracking energy, mood, libido, sleep, and side effects weekly
What to Do Next
If you're on hormone therapy and haven't had labs checked in more than 6 months, the next step is a structured follow-up — not waiting for symptoms to tell you something is wrong. A direct primary care membership at GoodLife Health includes ongoing lab monitoring and protocol adjustment.
FAQ
How often should hormone levels be checked? At 6-8 weeks after starting or changing any dose, then at 3 months, 6 months, and every 6-12 months once stable. Thyroid labs are rechecked 6 weeks after any dose change.
What labs should be monitored on testosterone therapy? Trough testosterone, estradiol, hematocrit, and PSA (annually). LH and FSH are checked if fertility is a concern. Lipid panel is checked annually.
What labs should be monitored on estrogen therapy? Estradiol, progesterone, and endometrial monitoring (annual ultrasound on continuous therapy). TSH is checked because estrogen affects thyroid binding.
Can symptoms replace lab monitoring? No. Symptoms are unreliable for dose adjustment — they can improve before levels are stable, or persist despite normal levels. Labs and symptoms together are the standard.
What causes hormone levels to drift over time? Weight changes, aging (SHBG shifts), stress, sleep disruption, new medications, seasonal vitamin D variation, and changes in insulin sensitivity. All of these can change the effective hormone level even if the dose hasn't changed.
Should I track my own lab results? Yes. Maintain a record of every lab result, the dose at the time of the draw, and any symptom changes. This history is invaluable for long-term protocol management and when switching clinicians.
What happens if I skip follow-up labs? The protocol may become under-dosed (levels drift below target) or over-dosed (side effects develop gradually). By the time symptoms signal a problem, the drift has usually been present for weeks or months.
One Last Thing
The patients whose hormone protocols work for years — not months — are the ones whose clinicians recheck labs on a schedule, watch for drift, and adjust before symptoms appear. Hormone therapy is a dynamic system, not a static prescription. The lab schedule is not bureaucracy; it's the difference between a protocol that keeps working and one that silently stops.
Related Guides
Related Reading
- Labs Before Hormone Therapy 2026: The Non-Negotiable Panel
- Best Direct Primary Care for Hormone Therapy in 2026
- Best Telehealth Clinics for HRT in 2026: How to Choose
- Best Hormone Optimization Clinics for Women in 2026
References
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229